Information:
Error:
ID
34565
Description
Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone; ODM derived from: https://clinicaltrials.gov/show/NCT01516424
Link
https://clinicaltrials.gov/show/NCT01516424
Keywords
Versions (1)
- 1/19/19 1/19/19 -
Copyright Holder
see on clinicaltrials.gov
Uploaded on
January 19, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Schizophrenia NCT01516424
Eligibility Schizophrenia NCT01516424
- StudyEvent: Eligibility
Similar models
Eligibility Schizophrenia NCT01516424
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
subject met dsm-iv-tr criteria for a primary diagnosis of schizophrenia
boolean
ID.2
Item
patients are 18≤age≤65 years of age on the day when informed consent is obtained.
boolean
ID.3
Item
subject had a panss total score ≥70 and 120≥ at screening
boolean
ID.4
Item
subject had a score ≥4 on the panss at screening and baseline.
boolean
ID.5
Item
subjects are willing and able to comply with study protocol including treatment in hospital.
boolean
ID.6
Item
subjects or their legal guardians have signed the written informed consent form.
boolean
ID.7
Item
the subject was treatment with other investigate product within 30 days.
boolean
ID.8
Item
subject had a history of treatment with long-acting drug for anti schizophrenia within 56 days.
boolean
ID.9
Item
subject had a history of treatment with clozapine within 28 days.
boolean
ID.10
Item
subject with parkinson disease,etc
boolean